tbuckley/cabot-search huggingface dataset:
Correspondence on ‘2018 update of the EULAR recommendations for the management of hand osteoarthritis’
Authors: Young Sun Suh, Hyun-Ok Kim, Chang Han Lee, Chul Ho Yoon, Yun-Hong Cheon, Mingyo Kim, Hanna Lee, Sang-Il Lee
Journal: Annals of the Rheumatic Diseases (2020)

We were inspired by reading the article entitled ‘2018 update of the EULAR recommendations for the management of hand osteoarthritis’ by Kloppenburg et al .1 This up-to-date guideline will inform all health professionals and patients about optimal management by shared decision-making and may help advance research of hand osteoarthritis (OA). In overarching principles, this recommendation highlighted that the primary goal of managing hand OA is to control pain and stiffness and to optimise hand function and quality of life. This guideline also emphasised that management of hand OA should be individualised, taking into account its localisation and severity as well as comorbidities. The comorbidities should be thoroughly evaluated for individualised management of hand OA. Particularly, systemic diseases such as cardiac disease and/or hypertension, diabetes and depression are commonly accompanied with OA.2 Apart from systemic diseases, various localised upper extremity musculoskeletal diseases (UEMDs) also contribute to greater pain and poor performance-based physical function in people with hand OA. However, there have been few small studies in which carpal tunnel syndrome (CTS) or rotator cuff tear (RCT) has been commonly associated with hand OA.3 4 Moreover, …
TCT CONNECT-188 Safety and Feasibility of Intravascular Ultrasound Guided Robotic Percutaneous Coronary Intervention in Stable Angina
Authors: Takumi Kimura, Yorihiko Koeda, Masaru Ishida, Shohei Yamaya, Keiko Tsuji, Jun Kawakami, Takenori Ishisone, Iwao Goto, Tomonori Itoh, Yoshihiro Morino
Journal: Journal of the American College of Cardiology (2020)
Denatured corona proteins mediate the intracellular bioactivities of nanoparticles via the unfolded protein response
Authors: Shang Liu, Zhenzhen Wang, Xinbang Jiang, Jingjing Gan, Xuejiao Tian, Zhen Xing, Yiqing Yan, Jiahui Chen, Junfeng Zhang, Chunming Wang, Lei Dong
Journal: Biomaterials (2020)
Treatise on the Principles and Practice of Medicine.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Psychological outcomes of low-dose CT lung cancer screening in a multisite demonstration screening pilot: the Lung Screen Uptake Trial (LSUT)
Authors: Sonja Kummer, Jo Waller, Mamta Ruparel, Stephen W Duffy, Samuel M Janes, Samantha L Quaife
Journal: Thorax (2020)

Background Previous studies of psychological burden in low-dose CT (LDCT) lung cancer screening trials may lack generalisability due to participation bias and control arms having elevated distress. Methods Current and former smokers (n=787, aged 60–75) within a real-world screening demonstration pilot completed measures of lung cancer worry at three time points (T 0 : appointment, T 1 : next day, T 2 : 3 months) and anxiety and depression at two time points (T 0 and T 2 ). A ‘screening unaware’ community sample (n=383) with the same age and smoking characteristics completed these measures once (T 0 ). Mean scores were compared by sample type and LDCT result. Results Compared with the community sample (T 0 ), mean scores were higher in the screening sample, and statistically significantly increased in adjusted analyses, for lung cancer worry at T 0 and T 2 (mean (M): 9.32; 95% CI 8.96 to 9.69 vs M: 11.34; 11.09 to 11.59 and M: 11.88; 11.49 to 12.27), for anxiety at T 0 and T 2 (M: 3.32; 2.94 to 3.70 vs M: 4.73; 4.42 to 5.04 and M: 5.78; 5.33 to 6.23) and depression at T 2 (M: 3.85; 3.44 to 4.27 vs M: 4.15; 3.76 to 4.55). Scores were highest for those with indeterminate (eg, T 2 anxiety M: 6.93; 5.65 to 8.21) and incidental findings (primary care follow-up M: 5.34; 4.67 to 6.02) and those ineligible for screening (M: 6.51; 5.25 to 7.77). Being female, younger, not in paid employment, not married/cohabiting with a partner and lower education predicted poorer psychological outcomes at T 0 , but not T 2 after adjusting for baseline scores. Mean scores remained within ‘normal’ clinical ranges. Conclusion Psychological distress was raised among high-risk individuals undergoing LDCT screening in a real-world setting, but overall differences were unlikely to be clinically meaningful. It will be critical to monitor the psychological impact of services longitudinally across diverse settings, including subgroups vulnerable to clinically elevated distress. Trial registration The Lung Screen Uptake Trial was registered prospectively with the International Standard Registered Clinical/soCial sTudy (ISRCTN) (Number: NCT21774741 ) on 23 September 2015 and the National Institutes of Health ClinicalTrials.gov database ( NCT02558101 ) on 22 September 2015.
Alterations to <i>DNMT3A</i> in Hematologic Malignancies
Authors: Kartika Venugopal, Yang Feng, Daniil Shabashvili, Olga A. Guryanova
Journal: Cancer Research (2020)

In the last decade, large-scale genomic studies in patients with hematologic malignancies identified recurrent somatic alterations in epigenetic modifier genes. Among these, the
Letter to the Editor: The Limited Functions and Mechanisms of CircASAP1 as a Sponge of Onco‐microRNAs
Authors: Ye‐Zhao Wang
Journal: Hepatology (2020)

Supported by grants from the National Undergraduate Training Program for Innovation and Entrepreneurship (201811646025, to Y.W.), the Student Research and Innovation Program of Ningbo University (2017SRIP1918, 2018SRIP2507, and 2019SRIP1902, to Y.W.), and the K.C. Wong Magna Fund in Ningbo University. Potential conflict of interest: Nothing to report. [Correction added on October 11, 2021, after first online publication: The corresponding author's affiliation was corrected to the online version of the article.] TO THE EDITOR: Hu et al. reported on the functional mechanisms, likely tumorigenesis‐promoting mechanisms, and the potential clinical applications related to the circular RNA (circRNA) derived from exons 2 and 3 of the ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP) gene (circASAP1), which serves as a noninvasive prognostic predictor in hepatocellular carcinoma (HCC) metastasis and prognosis.(1) While this article will bring important roles and high potential clinical application value for patients with HCC, there remains substantial evidence to warrant concerns over the limited functions and mechanisms of circASAP1 as a sponge of onco‐microRNAs (miRNAs).(2,3) In their manuscript, the authors have made some strong comments: "Many circRNAs contain potential miRNA response elements, which suggests that circRNAs can act as miRNA sponges, forming a circRNA–miRNA–mRNA axis to exert their biological roles," "CircASAP1 is a sponge for miR‐326 and miR‐532‐5p," "CircASAP1 promotes HCC metastasis and progression by sponging miR‐326 and miR‐532‐5p," and "Theoretical and experimental research has shown that some circRNAs function as sponges to arrest microRNA (miRNA) functions."(1) Indeed, it was reported that most circRNAs, which are much less abundant than onco‐miRNAs, were not predicted to function sponging of onco‐miRNAs nearly as effectively as cerebellar degeneration related protein 1 antisense RNA (CDR1as).(2,3) CDR1as (also known as ciRS‐7, one of the best‐known circRNAs) has the capacity to bind to up to 20,000 miR‐7 molecules per cell, harbors over 70 selectively conserved miRNA target sites to miR‐7, and stands alone as the most compelling onco‐miRNA sponge for any conserved microRNA seed family.(2,3) Therefore, the authors should have discussed the limited functions and mechanisms of circRNAs as sponges of onco‐microRNAs and added more details about the potential implications and clinical significance of onco‐miRNAs.
TCT CONNECT-312 IVUS Predictors for Bailout Left Circumflex Stenting After an Initial Strategy of Provisional Stenting When Treating Distal Left Main Bifurcation Lesions
Authors: Xun Hu, Gary Mintz, Jing Kan, Adrian Banning, Bela Merkely, Dimitrios Karmpaliotis, Ajay Kirtane, Jeffrey Moses, Shao-Liang Chen, Gregg Stone, Akiko Maehara
Journal: Journal of the American College of Cardiology (2020)
Cellular vacuolization and apoptosis induced by hepatitis B virus large surface protein
Authors: Ngee-Chih Foo, Byung Y. Ahn, Xiaohong Ma, William Hyun, T. S. Benedict Yen
Journal: Hepatology (2002)

Fibrosing cholestatic hepatitis (FCH) is a rapidly progressive form of viral hepatitis B that occurs in severely immunosuppressed patients. Pathologically, the liver in FCH is characterized by widespread hepatocyte vacuolization and apoptosis, which, in contrast to more common forms of hepatitis B, is only rarely associated with significant inflammation. Therefore, it has been proposed that, in FCH, hepatocytes may be injured by a direct cytopathic effect of the virus rather than by the host immune response. In support of this hypothesis, we present evidence that cultured hepatoma cells that had been transfected with a plasmid selectively expressing the viral large surface protein form numerous large vacuoles and undergo apoptosis. The similarity of the cytopathology in FCH in vivo and in these transfected cells in vitro strongly implicates the large surface protein as the direct cause of this acute liver disease. This conclusion is further supported by the published demonstration that hepatocytes tend to accumulate large surface protein in FCH, which may reflect its overexpression by the virus. In conclusion, our data implicate the large surface protein as a major cause of hepatocyte injury in fibrosing cholestatic hepatitis. (Hepatology2002;36:1400-1407).
AB0669 PARTICULARITIES OF TUNISIAN FEMALE AXIAL SPONDYLOARTHRITIS
Authors: K. Ben Abdelghani, Y. Gzam, A. Fazaa, S. Miladi, K. Ouenniche, S. Kassab, L. Souabni, S. Chekili, A. Laatar
Journal: Annals of the Rheumatic Diseases (2020)

Background: Axial spondyloarthritis (ax-SpA) is a chronic rheumatic disease that mainly affects men. However, the female form of ax-SpA remains insufficiently studied. Objectives: The aim of this study was to determine the clinical characteristics, the disease activity and the functional impact of female ax-SpA in comparison with male ax-SpA. Methods: This is a retrospective study including patients diagnosed with ax-SpA fulfilling the criteria of the Assessment of SpondyloArthritis international Society (ASAS) 2009. Clinical parameters, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath ankylosing spondylitis disease activity index (BASDAI) and Bath ankylosing spondylitis functional index (BASFI) were compared between groups of female and male ax-SpA. Results: Two hundred ax-SpA patients were included with 31% of female (n=62) and a mean age of 43,3 ± 11,2 years. The mean age at onset of symptoms was 31,8 ± 8,9 years for women and 25,3 ± 9,1 years for men (p &lt;0,0001). The mean age at diagnosis was 36,4 ± 9,6 years for women and 31,7 ± 10,4 years for men (p = 0,003). Ax-SpA with juvenile onset was noted in 1,7% of women and 12,1% of men (p = 0,02). Male ax-SpA were significantly more smokers (46.8% vs 5.4%; p &lt;0.001). The mean duration of morning stiffness was 11,3 ± 9,2 minutes for women versus 21,6 ± 19,3 minutes for men (p = 0,005). The mean ESR was 42,4 ± 29,8 mm for women and 28,3 ± 23,4 mm for men (p = 0,001). Radiographic sacroiliitis was present in 69,3% of women versus 84,7% of men (p = 0,01). The use of anti-TNF alpha was less frequent in women (29% vs 48,5%; p = 0,01). Our study didn’t found a statistically significant difference in peripheral manifestations, extraarticular manifestations, CRP, BASDAI and BASFI between the two groups. Conclusion: Female ax-SpA seems to have a better prognosis than male with older age in disease onset, less inflammation, less radiographic sacroiliitis and less use of biological treatments. References: [1]Rusman T, et al. Curr Rheumatol Rep. 2018; 20(6). [2]Siar N, et al. Curr Rheumatol Rev. 2019; Disclosure of Interests: None declared
TCT CONNECT-55 Short Duration of Dual Antiplatelet Therapy After PCI With DES: An Updated Meta-Analysis of Randomized Controlled Trials
Authors: Ahmed Elzanaty, Salik Nazir, Azizullah Beran, Eman Elsheikh, Mohammed Mhanna, Khalid Changal, Keerat Rai Ahuja, Ehab Eltahawy
Journal: Journal of the American College of Cardiology (2020)
A Man in His 90s With Progressive Hoarseness—What is the Cause?
Authors: Chunyan Jiang, Hongwei Li, Tingting Zhang
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
FRI0148 2-years bone mineral density follow-up in patients with systemic lupus erythematosus
Authors: J Rosa, V Tesa, C Dostál, J Zadina, H Hulejová, J Kafková, I Malá, E Rogie
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Systemic lupus erythematosus (SLE) and its treatment comprises several potential risk factors of osteoporosis. <h3>Objectives</h3> We evaluated bone mineral density (BMD) in a cohort of ambulatory patients with SLE and determined the influence of corticosteroids and disease-related variables at the baseline and during 24-months follow-up. <h3>Methods</h3> BMD of the lumbar spine, proximal femur, and total body was measured by dual energy X-ray absorptiometry (DEXA) in 61 SLE patients (52 premenopausal women, 9 men; mean age 32,3 and 36 years, respectively) and 61 healthy controls matched for age and sex. Several disease-related variables including treatment characteristics were recorded. 50 patients (40 women, 9 men) and 37 patients (31 women, 6 men) were followed for another 12 and 24 months, respectively. <h3>Results</h3> With few exceptions the BMD values of all sites were significantly reduced in both women and men (p values &lt;0,001–0,05) as compared to controls. During 12 months of follow-up a significant BMD decrease was seen in neck (both women and men), total body (women) and in proximal femur (men). In women current corticosteroid dose adversely influenced total body mineral content development. Continuous BMD loss has been detected during another 12 months in a subgroup of patients taking &gt;10 mg prednisone daily. Generally, there was no further BMD decline in the second year of study, presumably due to lower average daily prednisone dose compared to that at the start of study (10,0 vs. 14,3 mg in women, 11,3 vs. 22,4 in men). <h3>Conclusion</h3> BMD in premenopausal women and in men with SLE is significantly reduced at all measured sites and is adversely influenced by duration of the illness (proximal femur) and prednison cumulative dose (lumbar spine, total body). This decline occurs presumably early during the corticosteroid treatment and further bone loss is limited to patients taking &gt;10 mg prednisone daily. This work has been supported by IGA MZ ÈR 5035–3.
TCT CONNECT-267 BIOVITESSE—Multicenter Prospective First-In-Man Study of a New Polymer-Free Drug-Coated Stent With Ultrathin Struts: Clinical Study Outcome
Authors: Lorenz Raber, Jonas Haener, Ron Waksman, Thomas Lüscher, Marco Moccetti, Stefan Stortecky, Stephane Fournier, Hector Garcia-Garcia, Patrick Siegrist
Journal: Journal of the American College of Cardiology (2020)
Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw
Authors: Lina He, Xiangyu Sun, Zhijie Liu, Yanfen Qiu, Yumei Niu
Journal: International Journal of Oral Science (2020)

Abstract Medication-related osteonecrosis of the jaw (MRONJ) is a serious side effect of bone-modifying agents and inhibits angiogenesis agents. Although the pathogenesis of MRONJ is not entirely clear, multiple factors may be involved in specific microenvironments. The TGF-β1 signalling pathway may have a key role in the development of MRONJ. According to the clinical stage, multiple variables should be considered when selecting the most appropriate treatment. Therefore, the prevention and management of treatment of MRONJ should be conducted in patient-centred multidisciplinary team collaborative networks with oncologists, dentists and dental specialists. This would comprise a closed responsibility treatment loop with all benefits directed to the patient. Thus, in the present review, we aimed to summarise the pathogenesis, risk factors, imaging features, clinical staging, therapeutic methods, prevention and treatment strategies associated with MRONJ, which may provide a reference that can inform preventive strategies and improve the quality of life for patients in the future.
OP0129 CAPS CRITERIA FAIL TO IDENTIFY MOST SEVERE PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME ADMITTED TO THE INTENSIVE CARE UNITWITH A NEW THROMBOTIC MANIFESTATION
Authors: Marc Pineton de Chambrun, Alexis Mathian, Alain Combes, Charles-Edouard Luyt, Zahir Amoura
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Catastrophic antiphospholipid syndrome (CAPS) is the most severe manifestation of antiphospholipid syndrome (APS), characterized by the simultaneous occurrence of thrombosis in multiple organs. <h3>Objectives</h3> The objectives of this study were to evaluate the distribution and the prognosis of CAPS criteria in APS patients admitted to the intensive care unit (ICU) with acute thrombotic manifestation. <h3>Methods</h3> We conducted a multicentre retrospective study, from January 2000 to September 2018, including all APS patient admitted to 24 French ICUs with any new thrombotic (arterial, venous or microvascular) manifestation. <h3>Results</h3> 134 single patients were admitted to the ICU for 152 episodes. The number of patients with definite CAPS, probable CAPS and no CAPS was: 11 (7.2%), 60 (39.5%) and 81 (53.5%) respectively. We compared patients with definite/probable CAPS (group 1, n=61) and no CAPS (group 2, n=73). General characteristics and APS-involved organs are reported in Table 1. APS characteristics and biological findings before admission were comparable between both groups. In-ICU and in-hospital length of stay, day-0 SAPS II and day-0 SOFA in-ICU severity scores and Charlson comorbidity score were not different between group 1 and 2. The median [IQR25-75] number of organs involved (4 [3-4] vs. 2 [1-3], p&lt;0.0001) and the frequency of proven microvascular thrombosis (23 (37.7%) vs. 8 (11%), p&lt;0.0001) were higher in group 1. Treatment and outcomes are reported in Table 2. Aside plasmapheresis there was no difference in terms of APS treatments between both groups. The in-hospital mortality was not different between patient with definite/probable CAPS and no CAPS (23% vs. 28.8% respectively, p=0.4). The Kaplan-Meier curve of cumulative probability of survival retrieve no difference of survival between both groups (log-rank test p=0.5, Figure 1). <h3>Conclusion</h3> In this study<b>,</b> CAPS criteria were not associated with mortality in APS patients admitted to the ICU with new thrombotic manifestations. Further studies are needed to evaluate the accuracy of CAPS criteria in this population. <h3>Disclosure of Interests</h3> None declared
Airspace Macrophages and Monocytes Exist in Transcriptionally Distinct Subsets in Healthy Adults
Authors: Kara J. Mould, Camille M. Moore, Shannon A. McManus, Alexandra L. McCubbrey, Jazalle D. McClendon, Christine L. Griesmer, Peter M. Henson, William J. Janssen
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Macrophages are the most abundant immune cell in the alveoli and small airways and are traditionally viewed as a homogeneous population during health. Whether distinct subsets of airspace macrophages are present in healthy humans is unknown. Single-cell RNA sequencing allows for examination of transcriptional heterogeneity between cells and between individuals. Understanding the conserved repertoire of airspace macrophages during health is essential to understanding cellular programing during disease.
TCT CONNECT-58 Evaluation of Antithrombotic Strategies Before and After the First Month of Therapy: Landmark Analysis of the RE-DUAL PCI Trial
Authors: Deepak Bhatt, Philippe Gabriel Steg, Jonas Oldgren, Michael Maeng, Uwe Zeymer, Sigrun Halvorsen, Stefan Hohnloser, Gregory Lip, Takeshi Kimura, Matias Nordaby, Miede Corinna, Jurrien Ten Berg, Christopher Cannon, Benjamin Peterson
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-392 Prognostic Impact of Discordance Between Coronary Flow Reserve and the Index of Microcirculatory Resistance After Percutaneous Coronary Intervention
Authors: Christopher Wong, Takeshi Nishi, Martin Ng, Andy Yong, Cuneyt Ada, Tsunekazu Kakuta, Emanuele Barbato, Katsuhisa Waseda, Tetsuya Amano, Atsushi Hirohata, William Fearon
Journal: Journal of the American College of Cardiology (2020)
Noninvasive Detection of Active Microcalcification in an Occlusive Peripheral Vascular Aneurysm Using 18F-NaF PET/CT Imaging
Authors: Susan Natalie Eisert, Ting-Heng Chou, Adam J. Bobbey, Michael R. Go, Mitchel R. Stacy
Journal: Clinical Nuclear Medicine (2020)

Abstract A 65-year-old man with an occluded popliteal artery aneurysm and calf claudication underwent PET/CT imaging with 18 F-NaF to assess the status of active microcalcification in the aneurysm site and additional lower extremity arteries. CT imaging revealed macrocalcification of the aneurysm that colocalized with elevated retention of 18 F-NaF on PET images. PET/CT detected additional distal arterial sites with focal uptake of 18 F-NaF that did not coincide with CT-detectable macrocalcification. This report highlights a case of active microcalcification in an occlusive peripheral aneurysm using PET/CT. PET/CT may provide molecular insight into the remodeling of lower extremity aneurysms and atherosclerotic lesions.